SG11201801295WA - New crystal of piperazine compound - Google Patents

New crystal of piperazine compound

Info

Publication number
SG11201801295WA
SG11201801295WA SG11201801295WA SG11201801295WA SG11201801295WA SG 11201801295W A SG11201801295W A SG 11201801295WA SG 11201801295W A SG11201801295W A SG 11201801295WA SG 11201801295W A SG11201801295W A SG 11201801295WA SG 11201801295W A SG11201801295W A SG 11201801295WA
Authority
SG
Singapore
Prior art keywords
new crystal
piperazine compound
piperazine
compound
crystal
Prior art date
Application number
SG11201801295WA
Inventor
Shinichi Aoki
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG11201801295WA publication Critical patent/SG11201801295WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201801295WA 2015-09-17 2016-09-16 New crystal of piperazine compound SG11201801295WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015184022 2015-09-17
PCT/JP2016/077547 WO2017047791A1 (en) 2015-09-17 2016-09-16 New crystal of piperazine compound

Publications (1)

Publication Number Publication Date
SG11201801295WA true SG11201801295WA (en) 2018-03-28

Family

ID=58289428

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912021VA SG10201912021VA (en) 2015-09-17 2016-09-16 New crystal of piperazine compound
SG11201801295WA SG11201801295WA (en) 2015-09-17 2016-09-16 New crystal of piperazine compound

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201912021VA SG10201912021VA (en) 2015-09-17 2016-09-16 New crystal of piperazine compound

Country Status (22)

Country Link
US (1) US20180258069A1 (en)
EP (1) EP3351542B1 (en)
JP (1) JP6944372B2 (en)
KR (1) KR102587705B1 (en)
CN (1) CN108026068A (en)
AU (1) AU2016324121B2 (en)
BR (1) BR112018003448A2 (en)
CA (1) CA2999009C (en)
DK (1) DK3351542T3 (en)
ES (1) ES2901157T3 (en)
HK (1) HK1247921A1 (en)
HU (1) HUE057813T2 (en)
MA (1) MA42839A (en)
MX (1) MX2018003320A (en)
MY (1) MY193595A (en)
PH (1) PH12018500399A1 (en)
PL (1) PL3351542T3 (en)
PT (1) PT3351542T (en)
RU (1) RU2018113722A (en)
SG (2) SG10201912021VA (en)
TW (1) TWI707851B (en)
WO (1) WO2017047791A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024143236A1 (en) * 2022-12-26 2024-07-04 大鵬薬品工業株式会社 Crystals of acetate hydrochloride

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102070614B (en) * 2005-05-23 2014-01-15 诺华股份有限公司 Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
BRPI1009212B8 (en) * 2009-03-09 2024-03-12 Taiho Pharmaceutical Co Ltd Piperazine compound capable of inhibiting prostaglandin d synthase, its uses and pharmaceutical composition
US8765750B2 (en) * 2010-01-22 2014-07-01 Taiho Pharmaceutical Co., Ltd. Piperazine compound having a PGDS inhibitory effect
JP6130701B2 (en) * 2012-04-01 2017-05-17 エシャシ ファーマ リミテッドEshyasi Pharma Limited Industrial production method of (2RS) -1-dimethylamino-3- {2- [2- (3-methoxyphenyl) ethyl] phenoxy} propan-2-yl hydrogen succinate hydrochloride
JP5999686B2 (en) * 2012-04-05 2016-09-28 ロンシール工業株式会社 Heat-resistant polylactic acid-based molded body and method for producing the same
BR112015005489B1 (en) * 2012-09-19 2022-07-12 Taiho Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH IMPROVED DISSOLUTION AND/OR ABSORPTION

Also Published As

Publication number Publication date
MX2018003320A (en) 2018-05-30
HUE057813T2 (en) 2022-06-28
JP6944372B2 (en) 2021-10-06
TW201720818A (en) 2017-06-16
AU2016324121A1 (en) 2018-04-26
HK1247921A1 (en) 2018-10-05
EP3351542A4 (en) 2019-04-24
EP3351542B1 (en) 2021-11-17
WO2017047791A1 (en) 2017-03-23
DK3351542T3 (en) 2022-01-03
RU2018113722A3 (en) 2019-12-23
CN108026068A (en) 2018-05-11
WO2017047791A9 (en) 2017-05-18
CA2999009C (en) 2023-05-23
KR20180051628A (en) 2018-05-16
PH12018500399A1 (en) 2018-08-29
PT3351542T (en) 2021-12-21
MA42839A (en) 2018-07-25
US20180258069A1 (en) 2018-09-13
EP3351542A1 (en) 2018-07-25
MY193595A (en) 2022-10-19
TWI707851B (en) 2020-10-21
KR102587705B1 (en) 2023-10-12
CA2999009A1 (en) 2017-03-23
BR112018003448A2 (en) 2018-09-25
JPWO2017047791A1 (en) 2018-07-05
AU2016324121B2 (en) 2020-08-20
PL3351542T3 (en) 2022-02-14
ES2901157T3 (en) 2022-03-21
RU2018113722A (en) 2019-10-18
SG10201912021VA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
HK1249905A1 (en) Heterocyclic compounds as lsd1 inhibitors
IL255817B (en) Synthesis of heterocyclic compounds
IL250709A0 (en) Aminopyrimidinyl compounds as jak inhibitors
SG11201706729SA (en) Derivatives of sobetirome
HK1245770A1 (en) Novel crystal of uracil compound
IL251780A0 (en) New compounds as nik inhibitors
SI3380554T1 (en) Crystalline forms of per-chloro-gamma-cyclodextrines
HK1244274A1 (en) Crystalline forms of c21h22ci2n4o2
IL253479A0 (en) Crystalline forms of efinaconazole
SI3159335T1 (en) Novel heterocyclic compound
HUE050745T2 (en) Use of levelling compound
SI3424930T1 (en) Crystal of compound having jak-inhibiting activity
HK1247921A1 (en) New crystal of piperazine compound
EP3212611A4 (en) Crystal forms of verapamil hydrochloride
PT3395819T (en) Crystal form of substituted aminopyran derivative
HUP1500506A2 (en) Salts of palbociclib